You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.
FIND aims to make easy-to-use self-tests available in low- to middle-income countries and has set aside an initial budget of $15 million for the initiative.
FIND said it will announce agreements that will enable the distribution of more than 250 million rapid antigen tests per year to low- and middle-income countries.
The funding from the Canadian government will facilitate the optimization of new, quality rapid diagnostic tests for affordability and ease of use.
The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.
FIND said the funds were awarded as part of the Access to COVID-19 (ACT) Accelerator Diagnostics Pillar to accelerate testing to help mitigate the pandemic.
The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.
The group is aiming to develop a fingerstick test to detect circulating levels of an antigen that is secreted continuously by living schistosomes from various species.
Over six months, Abbott and SD Biosensor will provide rapid antigen tests to a variety of countries at a maximum price of $5 per test.
FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.